Can targeting ADP-Ribosylhydrolases offer therapeutic benefits?
As key regulators of protein function and cellular stress responses, ADP-Ribosylhydrolases present attractive targets for drug development. Inhibitors or modulators of these enzymes could potentially be used to enhance the efficacy of chemotherapy by sensitizing cancer cells to DNA-damaging agents. Furthermore, enhancing hydrolase activity might protect normal cells from the adverse effects of environmental toxins and radiation, offering a protective strategy in toxicological contexts.
